Lange E, König L, Kühne G E, Liefke T
Psychiatr Neurol Med Psychol (Leipz). 1975 Jun;27(6):360-5.
Until now the "neuroleptic threshold" (Haase) was considered to be the efficiency criterion of the antipsychotic effect of a neuroleptic substance and it was thought therefore that the extrapyramidal symptoms were a necessary although undesired side effect. The benodiazepine derivative Leponex developed by Sandox - Basel upsets this view because it has an excellent antipsychotic effect without creating definite extrapyramidal symptoms. It is noted for its quick soporfic effect after only a few minutes, for subdueing psychopathological productivity in a very impressive way, for acting rapidly on the "plus"-symptomatology typical of psychosis, as early as in the first days of treatment, and for its equally visible effect on the "minus"-symptoms, typical of psychosis, in the last third of an average period of treatment lasting 40 days. The clinic using Leponex (Dresden, Halle, Brandenburg-Görden) belonged to the clinical application programme of the Sandox - Basel firm. The article gives a summary of essential results and particulars about the treatment. A detailed evaluation of the case sheets which are at present being statistically reviewed will be given in the next paper.
直到现在，“抗精神病药物阈值”（哈泽）一直被视为抗精神病药物抗精神病作用的疗效标准，因此人们认为锥体外系症状是一种必要的、尽管是不良的副作用。巴塞尔山德士公司研发的苯二氮䓬衍生物氯氮平打破了这一观点，因为它具有出色的抗精神病作用，却不会产生明显的锥体外系症状。它以仅几分钟后就能产生快速的催眠效果、以非常显著的方式抑制精神病理活动、早在治疗的第一天就能迅速作用于精神病典型的“阳性”症状学以及在平均为期40天的治疗的最后三分之一时间里对精神病典型的“阴性”症状产生同样明显的效果而闻名。使用氯氮平的诊所（德累斯顿、哈雷、勃兰登堡 - 戈尔登）属于巴塞尔山德士公司的临床应用项目。本文给出了治疗的基本结果和详情总结。下一篇论文将对目前正在进行统计审查的病历进行详细评估。
